Literature DB >> 9149329

Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: relationships with immune-inflammatory markers.

M Maes1, I De Meester, R Verkerk, P De Medts, A Wauters, G Vanhoof, E Vandoolaeghe, H Neels, S Scharpé.   

Abstract

Previous research in this laboratory has shown that major depression is accompanied by decreased serum activity of dipeptidyl peptidase IV (DPP IV), a serine protease that cleaves N terminal dipeptides from peptides with penultimate proline or alanine. DPP IV is involved in the metabolism of peptides, T cell activation and proliferation, including the production of cytokines, such as interleukin-1 (IL-1) and IL-2. The aim of this study was to examine (i) serum DPP IV activity in major and treatment resistant depression (TRD) in relation to other established immune and inflammatory markers of that illness, and (ii) the effects of antidepressive treatment on DPP IV activity. Serum DPP IV activity was significantly lower in major depression and TRD than in normal controls. In normal and major depressed subjects, there were significant and positive relationships between serum DPP IV activity and total serum protein, serum albumin, zinc, iron and transferrin. In the group of depressed subjects, there were significant and positive relationships between serum DPP IV activity and number of CD4+T cells and CD4+/CD8+ T cell ratio. There were no significant effects of subchronic treatment with antidepressants on serum DPP IV activity. The findings suggest that: (i) lower serum DPP activity may occur in chronic depression, TRD as well as in the acute phase of major depression; (ii) lower serum DPP IV accompanies the 'chronic' acute phase response in depression; and (iii) serum DPP IV activity is tightly coupled to increased number of CD4+ T cells in depressed subjects, but not in normal controls. Our results do not exclude the possible effects of longer-term treatment with antidepressants on serum DPP-IV activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149329     DOI: 10.1016/s0306-4530(96)00040-6

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  8 in total

Review 1.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

2.  Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer.

Authors:  O J Cordero; D Ayude; M Nogueira; F J Rodriguez-Berrocal; M P de la Cadena
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

Review 3.  "Immune Gate" of Psychopathology-The Role of Gut Derived Immune Activation in Major Psychiatric Disorders.

Authors:  Leszek Rudzki; Agata Szulc
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

4.  Anxiety Is Associated With DPPIV Alterations in Children With Selective Mutism and Social Anxiety Disorder: A Pilot Study.

Authors:  Yulia Golub; Valeska Stonawski; Anne C Plank; Anna Eichler; Oliver Kratz; Regina Waltes; Stephan von Hoersten; Veit Roessner; Christine M Freitag
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157

5.  Towards a possible aetiology for depressions?

Authors:  Ying Liu; Tore Heiberg; Karl-Ludvig Reichelt
Journal:  Behav Brain Funct       Date:  2007-09-14       Impact factor: 3.759

6.  A Meta-Analysis of Oxidative Stress Markers in Depression.

Authors:  Tao Liu; Shuming Zhong; Xiaoxiao Liao; Jian Chen; Tingting He; Shunkai Lai; Yanbin Jia
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 7.  The opioid effects of gluten exorphins: asymptomatic celiac disease.

Authors:  Leo Pruimboom; Karin de Punder
Journal:  J Health Popul Nutr       Date:  2015-11-24       Impact factor: 2.000

8.  Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.

Authors:  John-Michael Gamble; Eugene Chibrikov; William K Midodzi; Laurie K Twells; Sumit R Majumdar
Journal:  BMJ Open       Date:  2018-10-08       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.